Picture of Adaptimmune Therapeutics logo

ADAP Adaptimmune Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Adaptimmune Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-70.1-95.5-137-130-158
Depreciation
Amortisation
Non-Cash Items3.1928.711.912.927.6
Unusual Items
Other Non-Cash Items
Changes in Working Capital7.21-45.34.7256135
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Cash from Operating Activities-54.3-104-113-53.610.7
Capital Expenditures-25-4.71-3.07-2.91-8.78
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-101-12.798-27684.6
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Cash from Investing Activities-126-17.594.9-27975.8
Net Issuance / Retirement of Stock
Cash from Financing Activities1041030.3663403.29
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-74.5-15.8-17.66.5890.2

Or unlock with your email

Or unlock with your email